Patients with bioprosthetic valves were excluded in the RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) and the ROCKET AF (Rivaroxaban Once Daily Direct Factor Xa Inhibitor Compared With Vitamin K Antagonist for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trials. Here, F10 is linked to atrial fibrillation.